INS and pancreatic insulinoma: A primary disease endpoint in TEDDY is islet autoimmunity (IA), defined as persistently positive for insulin autoantibodies (IAA), glutamic acid decarboxylase autoantibodies (GADA), or insulinoma-associated-2 autoantibodies (IA-2A) at two consecutive visits confirmed by the two TEDDY laboratories [18].